The long-term goal of this research is to understand the pathogenesis of Ebola virus infection at the molecular level. A potential bioterrorism agent, Ebola virus causes severe hemorrhagic disease in humans and is one of the most deadly human pathogens encountered to date, earning classification as a 'Category A Priority Pathogen' in the NIAID Biodefense and Emerging Infectious Disease Research Opportunities Program. Yet, neither therapeutic treatments nor protective vaccines are available to control this often lethal infection. The combination of a reverse genetics system for the generation of Ebola virus entirely from cloned cDNA and access to a biosafety level 4 facility has positioned the applicant to undertake the following specific aims: 1) To understand the regulation of Ebola viral transcription, in which bicistronic minireplicon and reverse genetics strategies will be used to assess the replicative significance of the unique features characterizing the Ebola virus genome, such as overlapping transcriptional stop/start signals and an unusually long intergenic region; 2) To clarify the mechanisms that drive the formation of infectious Ebola virus particles, in which the roles of the VP40 matrix protein and GP glycoprotein in particle formation and budding will be investigated; 3) To define the role of VP24 protein in Ebola viral replication, in which the intracellular localization of VP24, its association with cellular membranes and/or other viral proteins, and its function in virion budding and membrane fusion will be determined; and 4) To identify the factors and mechanisms responsible for the extreme virulence of Ebola virus infection, in which a murine model of Ebola virus infection will be used to screen mutations that may enhance or diminish viral pathogenicity. Moreover, using a wild-type Ebola virus, furin-mediated GP cleavage, or the mucin-like domain in GP, and the secreted glycoprotein, sGP, will also be evaluated for a possible contribution to Ebola virulence. Collectively, these studies will contribute to the deciphering of the molecular basis for the extreme virulence of this pathogen. Ultimately, the information gained could be exploited in the development of antiviral compounds and effective vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI055519-05
Application #
7189848
Study Section
Virology Study Section (VR)
Program Officer
Repik, Patricia M
Project Start
2003-09-01
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2009-02-28
Support Year
5
Fiscal Year
2007
Total Cost
$347,491
Indirect Cost
Name
University of Wisconsin Madison
Department
Pathology
Type
Schools of Veterinary Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Nanbo, Asuka; Watanabe, Shinji; Halfmann, Peter et al. (2013) The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. Sci Rep 3:1206
Olal, Daniel; Kuehne, Ana I; Bale, Shridhar et al. (2012) Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J Virol 86:2809-16
Dias, João M; Kuehne, Ana I; Abelson, Dafna M et al. (2011) A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol 18:1424-7
Makino, Akiko; Yamayoshi, Seiya; Shinya, Kyoko et al. (2011) Identification of amino acids in Marburg virus VP40 that are important for virus-like particle budding. J Infect Dis 204 Suppl 3:S871-7
Nanbo, Asuka; Imai, Masaki; Watanabe, Shinji et al. (2010) Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog 6:e1001121
Noda, Takeshi; Hagiwara, Kyoji; Sagara, Hiroshi et al. (2010) Characterization of the Ebola virus nucleoprotein-RNA complex. J Gen Virol 91:1478-83
Makino, Akiko; Kawaoka, Yoshihiro (2009) Generation of vero cells expressing ebola virus glycoprotein. J Vet Med Sci 71:505-7
Yamayoshi, Seiya; Noda, Takeshi; Ebihara, Hideki et al. (2008) Ebola virus matrix protein VP40 uses the COPII transport system for its intracellular transport. Cell Host Microbe 3:168-77
Watanabe, Shinji; Noda, Takeshi; Halfmann, Peter et al. (2007) Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J Infect Dis 196 Suppl 2:S284-90